Definitive Contract 75A50122C00036

Award Date 6/30/22
Potential Completion Date 8/29/25
Potential Value $407K
Ultimate Awardee
Danaher Corporation
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Miami, FL 33196, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $65,183,092 cost-sharing contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Beckman Coulter, Inc. to develop and commercialize a rapid antimicrobial susceptibility testing system that can deliver results within 4-6 hours. The contract has a performance period ending on May 20, 2028. Beckman Coulter, a subsidiary of Danaher Corporation, has previously been awarded federal contracts to provide clinical laboratory technologies, supplies,...
This is a $7,226,322.00 definitive contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Beckman Coulter Inc., a subsidiary of Danaher Corporation. The contract is for the provision of Beckman Coulter's Monocyte Distribution Width (MDW) and predictive analytic algorithms for sepsis detection. This contract was not set aside. The original federal contract opportunity was a Broad Agency Announcement from BARDA seeking...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Beckman Coulter, Inc., a subsidiary of Danaher Corporation. The contract, valued at $5,256.00, is a firm fixed-price purchase order for unspecified products or services related to the AMBIS #1710473 requirement. The contract does not have a set-aside designation, indicating Beckman Coulter's capabilities allow it to compete as a prime...
This is a delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to Beckman Coulter, Inc., a global manufacturer of biomedical testing equipment and solutions. The $24,188 firm-fixed-price contract has a completion date of May 5, 2029 and does not have a set-aside designation. Beckman Coulter, through its U.S. Customer Operations division, is an experienced federal contractor that...
This is a $894,490.80 firm fixed-price delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Beckman Coulter, Inc. The contract is for ARRA-funded software and equipment to support the NIAID's biomedical research and testing initiatives, including a Biomek system and XP controller. Beckman Coulter, a subsidiary of Danaher Corporation, is a manufacturer and provider of specialized laboratory...
Beckman Coulter Inc. was awarded a firm fixed price contract valued at $694,000 by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to develop the Monocyte Distribution Width (MDW) test for rapid detection of Multisystem Inflammatory Syndrome in Children (MIS-C) associated with COVID-19 in pediatric patients. This award was made under Special Instructions 019 to the department's Easy Broad Agency Announcement BAA-20-100-SOL-0002, which...
This is a delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to prime contractor Beckman Coulter, Inc. The $14,393.00 fixed-price level of effort contract is for the provision of laboratory instruments, reagents, software, maintenance, and related equipment and consumables to support federal biomedical research, testing, and healthcare initiatives. The award has no set-aside designation, indicating Beckman...
This federal contract award, HHSN272201400667P, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Beckman Coulter, Inc., a subsidiary of Danaher Corporation. The $3,161.20 firm fixed-price purchase order is for the procurement of specific reagents, including NKG2A PE, CD28 ECD, and CD27 CY5 PE, to support biomedical research and testing initiatives. The contract does not have a set-aside designation,...
This is a federal contract award made by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Beckman Coulter, Inc., a subsidiary of Danaher Corporation. The contract is for the delivery of laboratory instruments, reagents, software, maintenance, and related equipment and consumables to support biomedical research and healthcare initiatives across various government agencies. The award, valued at $3,617.00, is a firm fixed-price...
This federal contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, to Beckman Coulter, Inc. for sequencing services. The contract had a period of performance from September 4, 2013 to January 3, 2014 with a ceiling value of $14,386. The contract was a firm fixed price purchase order and was not set aside for any specific business type. Beckman Coulter, Inc. is a subsidiary of the Danaher Corporation, a...

This is a $406,514.30 firm fixed-price contract awarded by the Office of the Assistant Secretary for Preparedness and Response to Beckman Coulter, Inc., a subsidiary of Danaher Corporation, for an R&D effort to develop a rapid detection method for severe, dysregulated host immune responses to infection in pediatric patients. The contract is not set aside for any specific business category.

The contract supports the Major Program Code "BECKMAN COULTER: MDW FOR RAPID DETECTION OF SEVERE, DYSREGULATED HOST IMMUNE RESPONSE TO INFECTION" and has an ultimate completion date of August 29, 2025. It originated from a Broad Agency Announcement (BAA) issued by the Biomedical Advanced Research and Development Authority (BARDA) within the Department of Health and Human Services, which sought proposals for advanced diagnostic technologies to address host immune responses to infection.

Generated 6/27/25, 12:07 PM